查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999304

猪隻疫苗市场：2026-2032年全球市场预测（依疫苗类型、动物年龄、给药途径、包装、最终用户、疾病类型及通路划分）

Swine Vaccines Market by Vaccine Type, Animal Age, Route Of Administration, Packaging Type, End User, Disease Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，猪疫苗市场价值将达到 17 亿美元，到 2026 年将成长到 18.4 亿美元，到 2032 年将达到 29.9 亿美元，复合年增长率为 8.34%。

主要市场统计数据
基准年 2025 17亿美元
预计年份：2026年 18.4亿美元
预测年份：2032年 29.9亿美元
复合年增长率 (%) 8.34%

本书全面概述了现代猪疫苗接种策略如何在不断发展的全球供应链中支持猪群健康、生产韧性和农场层面的生物安全。

猪疫苗的现状在动物健康、食品安全和农业经济的交汇点上发挥着至关重要的作用。在现代生猪生产系统中，疫苗接种已从偶尔的干预措施发展成为猪群健康计画不可或缺的一部分，旨在保护生产力、动物福利以及公众对供应链的信心。集约化养殖、国际贸易以及病毒和细菌病原体的出现和再次出现所带来的日益增长的压力，进一步凸显了製定强有力的预防策略的必要性。因此，疫苗不再只是生物安全工具，而是直接影响农场韧性、合理使用抗生素和长期永续性的战略资产。

科技、监管和商业的变革如何结合起来，将疫苗转变为能够增强畜群健康韧性和营运效率的综合解决方案？

过去五年，随着技术、监管和商业动态的融合，猪隻疫苗生态系统经历了快速转型，并重塑了产业的格局。在技​​术层面，新型抗原平台和佐剂技术的进步提高了疫苗的预防效力，同时减少了副作用，并增强了疫苗与猪群日常管理操作的兼容性。同时，给药途径和包装方式的改进降低了操作的复杂性，并为大规模养猪场的群体免疫接种提供了更多实际选择。此外，病原体监测投入的增加也进一步巩固了这些创新成果，提高了疫苗株选择的准确性，并缩短了从发现病原体到采取针对性免疫措施的时间。

评估 2025 年关税措施对猪隻疫苗供应链和产业韧性的连锁影响，包括营运、采购和监管方面。

近期公布的2025年关税措施为猪疫苗供应链中的相关人员带来了新的挑战，影响到原料、成品以及跨境合作。这些关税改变了进口零件和成品疫苗的实际成本结构，迫使生产商和代工生产商重新评估其筹资策略和短期生产分配。在许多情况下，这些调整加速了特定生产流程的在地化进程，并促使企业摆脱对单一国家的依赖，实现采购来源多元化。同时，经销商和出口型供应商在跨境物流方面面临日益加剧的摩擦，这需要重新谈判商业条款并采取更灵活的库存管理策略。

对疫苗平台、动物年龄层、给药途径、包装、目标疾病、最终用户和分销管道进行详细的细分洞察，对于有针对性的商业化非常有用。

对细分市场的详细分析揭示了疫苗类型、动物年龄层、给药途径、包装、最终用户、目标疾病和分销管道等方面的不同趋势，每种因素都对产品开发和商业化产生独特的影响。疫苗类型包括DNA疫苗、灭活疫苗、减毒活病毒疫苗、重组疫苗、次单位疫苗疫苗和类毒素疫苗，每种疫苗都有其独特的风险效益比，影响整个生产系统的应用。动物年龄组包括种猪、肥育猪、生长猪、小猪和离乳仔猪。种猪进一步细分为公猪和母猪，并制定了特定的免疫接种时间和给药策略，以保护其繁殖能力和仔猪健康。

区域比较分析揭示了北美和南美、欧洲、中东和非洲以及亚太地区的市场如何寻求个人化的疫苗开发、分销和监管策略。

猪疫苗领域的区域趋势在成熟生产区和新兴成长市场之间存在显着差异，这影响着产品设计、监管合作和打入市场策略的优先事项。在美洲，高密度生产系统和一体化商业农场推动了对可扩展疫苗解决方案的需求，这些方案旨在优化劳动效率和群体免疫力。在该地区，稳健的供应链、可预测的监管流程以及与行业和兽医的紧密联繫对于支持检验的创新疫苗的快速推广至关重要。

主要企业如何平衡平台创新、製造能力和策略伙伴关係，以确保竞争优势并加速产品推广？

主要企业正以差异化的策略进军猪隻疫苗市场，这些策略体现了其产品组合的专业化、地理重点和生技药品生产能力。一些企业优先考虑平台多元化，并投资于新一代抗原技术和佐剂系统，以扩大对多种病原体的保护范围，同时减少不利事件。另一些企业则专注于创新给药途径和改进包装，以降低大规模商业营运中的给药复杂性和产品浪费。製造商与兽医服务提供者之间的策略合作有助于弥合「最后一公里」差距，并透过将培训、诊断支援和现场监测整合到商业服务中，促进疫苗的推广应用。

为产业领导者提供切实可行的策略和营运建议，以加强养猪系统中的疫苗创新、供应韧性和分销。

行业领导者应采取多管齐下的策略，将科学创新与切实可行的商业和营运措施相结合，以加强疫苗分发和市场韧性。首先，优先投资于能够提供广泛保护并快速适应新出现的病毒株的平台技术，将带来可持续的竞争优势。除了研发重点外，还应有针对性地改进给药方法和包装，以减少现场操作的阻力，并支持大规模疫苗宣传活动。

对混合方法研究方法进行了透明的概述，该方法整合了初步访谈、文献整合、细分映射和专家检验，以得出可操作的见解。

本分析所依据的研究结合了定性和定量方法，以确保对整个疫苗价值链进行全面而深入的洞察。主要研究包括对兽医、农场管理者、生产商、经销商和监管专家进行结构化访谈，以了解他们的实务经验和策略重点。次要研究则包括科学文献、监管指南、专利申请和生产系统分析的系统性回顾，以阐明技术和政策趋势的背景。这些资讯透过三角测量法进行整合，该方法结合了不同的观点并检验了新出现的主题。

简明扼要地阐述了将疫苗创新与猪隻健康和生产韧性的持续改善联繫起来所需的策略重点和协作努力。

疫苗接种仍然是保护猪隻健康、维持生产连续性、增强大众对猪肉供应链信心的最有效、最可推广的手段。目前，猪肉产业正处于转折点，科学进步、贸易环境变化以及畜牧养殖户实践的演变都要求生产者、兽医和政策制定者采取协调一致的应对措施。成功的关键在于将创新研发与切实可行的实施机制结合，加强地方层级的生产和供应韧性，并深化伙伴关係，将科学进步转化为日常畜群管理实践。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：猪疫苗市场：依疫苗类型划分

  • DNA疫苗
  • 灭活疫苗
  • 减毒活病毒疫苗
  • 重组疫苗
  • 次单位疫苗
  • 类毒素疫苗

第九章：猪疫苗市场：依动物年龄组别划分

  • 种猪
    • 种猪
    • 母猪
  • 肥育猪
  • 生长猪
  • 小猪
  • 断奶仔猪

第十章：猪隻疫苗市场：依给药途径划分

  • 注射
  • 鼻内
  • 口服

第十一章：猪疫苗市场：依包装类型划分

  • 多剂量瓶
  • 预填充式注射器
  • 管瓶

第十二章：猪疫苗市场：依最终用户划分

  • 商业农场
  • 研究机构
  • 动物诊所
  • 动物医院

第十三章：猪疫苗市场：依疾病类型划分

  • 经典猪瘟
  • 斑疹热
  • 肺炎霉浆菌
  • 猪环状病毒
  • 猪繁殖与呼吸综合症
  • 猪流感

第十四章：猪隻疫苗市场：依通路划分

  • 网路药房
    • 企业网站
    • EC平台
  • 动物诊所
  • 动物医院

第十五章：猪疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：猪疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 猪疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国猪疫苗市场

第十九章：中国猪疫苗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bimeda Holdings plc
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Bioveta, as
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • China Animal Husbandry Industry Co., Ltd.
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • HIPRA Laboratories, SA
  • Hygieia Biological Laboratories（private company）
  • IDT Biologika GmbH
  • Indian Immunologicals Limited
  • Intervet Inc.
  • Jinyu Bio-Technology Co., Ltd.
  • KM Biologics Co., Ltd.
  • Komipharm International Co., Ltd.
  • Kyoritsu Seiyaku Corporation
  • Lohmann Animal Health International GmbH & Co. KG
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-3A2E844FD486

The Swine Vaccines Market was valued at USD 1.70 billion in 2025 and is projected to grow to USD 1.84 billion in 2026, with a CAGR of 8.34%, reaching USD 2.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.70 billion
Estimated Year [2026] USD 1.84 billion
Forecast Year [2032] USD 2.99 billion
CAGR (%) 8.34%

A compelling overview of how modern swine vaccination strategies underpin herd health, production resilience, and farm-level biosecurity across evolving global supply chains

The swine vaccines landscape occupies a pivotal role at the intersection of animal health, food security, and agricultural economics. In modern pork production systems, vaccination has evolved from an occasional intervention into an integral component of herd health programs that safeguard productivity, animal welfare, and public confidence in supply chains. Growing pressures from intensification, global trade, and the emergence and re-emergence of viral and bacterial pathogens have sharpened the need for robust preventive strategies. As a result, vaccines are not merely biosecurity tools but strategic assets that directly influence farm resilience, antimicrobial stewardship, and long-term sustainability.

Beyond farm gates, the vaccine value chain comprises manufacturers, distributors, veterinarians, diagnostic providers, and regulatory authorities whose interactions determine how rapidly innovations translate into field impact. The convergence of advanced molecular platforms, improved delivery systems, and digital health tools is enabling more targeted immunization approaches. At the same time, demographic shifts in producer profiles, consolidation among commercial farms, and shifting consumer expectations create a complex operating environment. Consequently, stakeholders must balance immediate operational demands with mid- to long-term investments in research, cold-chain logistics, and training to realize the full potential of vaccination as a cornerstone of modern swine health management.

How converging technological, regulatory, and commercial shifts are transforming vaccines into integrated solutions that enhance herd health resilience and operational efficiency

The past five years have witnessed accelerated change in the swine vaccines ecosystem as technological, regulatory, and commercial dynamics converge to reshape industry boundaries. On the technological front, novel antigen platforms and adjuvant science have advanced protective performance while reducing adverse reactions and improving compatibility with herd management routines. Parallel developments in administration routes and packaging have lowered handling complexity and expanded practical options for mass immunization in large-scale operations. These innovations have been reinforced by increasing investment in pathogen surveillance, which improves the precision of vaccine strain selection and shortens the time from detection to targeted response.

Commercially, strategic partnerships and targeted investments in manufacturing capacity have improved responsiveness to regional demand fluctuations and supply interruptions. Regulatory agencies have moved toward clearer guidance on safety evaluation and field efficacy, encouraging more rigorous post-market surveillance and harmonized standards across jurisdictions. Meanwhile, digitalization-ranging from cold-chain telemetry to herd-level vaccine compliance tracking-has enhanced traceability and decision support for veterinarians and farm managers. Collectively, these shifts are transforming vaccines from single-product transactions into integrated solutions that combine scientific innovation, operational support, and data-driven insights to secure herd health at scale.

Assessment of the cascading operational, sourcing, and regulatory consequences that 2025 tariff actions have imposed on swine vaccine supply chains and industry resilience

Recent tariff measures announced in 2025 have introduced a new layer of complexity for stakeholders in the swine vaccines supply chain, affecting inputs, finished products, and cross-border collaboration. As tariffs alter the effective cost structure for imported components and finished doses, manufacturers and contract producers have had to reassess sourcing strategies and near-term manufacturing allocations. In many cases, the adjustments have accelerated efforts to localize certain production steps or to diversify procurement away from single-country dependencies. At the same time, distributors and export-oriented suppliers face elevated friction in cross-border logistics, necessitating renegotiated commercial terms and more dynamic inventory management.

These trade shifts have implications beyond immediate cost and logistics. They have increased the strategic value of regional regulatory alignment and mutual recognition agreements that reduce duplication of conformity assessments. In response, several firms have intensified engagement with regional authorities to streamline approvals and maintain uninterrupted access to essential biological inputs. From a research perspective, tariff-driven complexity has also encouraged closer collaboration between domestic manufacturers and academic institutions to insulate vaccine pipelines from international volatility. For end users, the net effect has been a renewed focus on resilience: producers are prioritizing vaccine regimens that minimize administration frequency and simplify handling, while veterinarians and supply partners emphasize robust contingency planning to sustain immunization programs amid shifting trade conditions.

Detailed segmentation insights across vaccine platforms, animal age classes, administration routes, packaging configurations, disease targets, end users, and distribution channels informing targeted commercialization

A granular look at segmentation reveals differentiated dynamics across vaccine type, animal age category, administration route, packaging format, end user, disease focus, and distribution channels, each with distinct implications for product development and commercialization. Vaccine type diversity spans DNA vaccine, inactivated vaccine, live attenuated vaccine, recombinant vaccine, subunit vaccine, and toxoid vaccine platforms, and each platform presents a unique risk-benefit profile that influences adoption across production systems. Animal age segments include breeders, finishers, growers, piglets, and weaners, with breeders further differentiated into boars and sows, creating specific immunization windows and dosing strategies to protect reproductive performance as well as piglet health.

Administration route choices-between injection, nasal, and oral delivery-affect labor requirements, stress on animals, and opportunities for mass vaccination. Packaging type options, including multi dose bottle, pre filled syringe, and vial formats, determine cold-chain demands, wastage rates, and field usability. End users range from commercial farms to research institutes, veterinary clinics, and veterinary hospitals, and each category has different purchasing behaviors, compliance expectations, and technical capabilities. Disease-focused segmentation covers classical swine fever, erysipelas, mycoplasma pneumonia, porcine circovirus, porcine reproductive and respiratory syndrome, and swine influenza; vaccines targeted at these conditions vary in immunogenic profile and regulatory pathway complexity. Distribution channels include online pharmacies, veterinary clinics, and veterinary hospitals, with online pharmacies further segmented into company websites and e-commerce platforms, a distinction that influences marketing, fulfillment, and after-sales support strategies. Together, these segmentation lenses enable a more nuanced approach to prioritizing R&D investments, tailoring messaging, and aligning commercial models with end-user realities.

Comparative regional analysis clarifying how the Americas, Europe Middle East & Africa, and Asia-Pacific markets demand tailored vaccine development, distribution, and regulatory strategies

Regional dynamics in the swine vaccines arena differ markedly across established production zones and emerging growth markets, shaping priorities for product design, regulatory engagement, and market access strategies. In the Americas, high-intensity production systems and integrated commercial farms drive demand for scalable vaccination solutions that optimize labor efficiency and herd-level immunity. This region places a premium on robust supply chains, predictable regulatory processes, and strong industry-veterinarian relationships that support rapid uptake of validated vaccine innovations.

In Europe, Middle East & Africa, regulatory complexity and diverse production models create both challenges and opportunities. Western European markets emphasize stringent safety and pharmacovigilance standards, while segments in Eastern Europe, the Middle East, and Africa often require cost-effective formulations and packaging that accommodate smaller-scale operations and variable cold-chain infrastructure. This heterogeneity encourages modular strategies that combine high-efficacy platforms with adaptive delivery and packaging options. In the Asia-Pacific region, dense production hubs and recurring disease pressures accelerate adoption of novel vaccine technologies and mass-administration approaches. The rapid expansion of contract manufacturing and growing capabilities in local R&D institutions have made the region a focal point for both innovation and regional supply security. Across all regions, digital distribution channels and e-commerce are emerging as complementary pathways to reach veterinary professionals and farm managers, particularly where traditional distribution networks face structural constraints.

How leading industry players are balancing platform innovation, manufacturing capacity, and strategic partnerships to secure competitive advantage and accelerate product adoption

Leading corporate participants approach the swine vaccines space with differentiated strategies that reflect portfolio specialization, geographic focus, and capabilities in biologics manufacturing. Some firms prioritize platform diversification, investing in next-generation antigen technologies and adjuvant systems to broaden protection across multiple pathogens while reducing adverse events. Other organizations concentrate on route-of-administration innovations and packaging improvements to lower administration complexity and product wastage in large-scale commercial operations. Strategic alliances between manufacturers and veterinary service providers help bridge the final-mile gap and strengthen adoption by integrating training, diagnostic support, and field monitoring into commercial offerings.

Manufacturing scale and the ability to meet stringent quality standards are central competitive levers, as are flexible contract manufacturing arrangements that enable rapid capacity scaling. Intellectual property management and a disciplined approach to regulatory submissions determine how quickly new vaccines can be commercialized across regions with divergent approval timelines. Finally, an increasing number of companies are pursuing collaborative research with academic centers and public veterinary institutes to accelerate translational studies while sharing development risk. These combined approaches underscore that success in the sector depends on a balanced emphasis across R&D, manufacturing excellence, regulatory strategy, and commercial execution.

Practical strategic and operational recommendations that industry leaders can implement to enhance vaccine innovation, supply resilience, and adoption in swine production systems

Industry leaders should adopt a multi-pronged playbook that aligns scientific innovation with pragmatic commercial and operational measures to strengthen vaccine uptake and market resilience. First, prioritizing investments in platform technologies that enable broad-spectrum protection and rapid adaptability to emerging strains will yield durable competitive advantages. Complementing that R&D focus with targeted improvements in administration methods and packaging will reduce field friction and support mass vaccination campaigns.

Second, building more resilient sourcing and manufacturing strategies is essential. This includes diversifying key input suppliers, expanding regional manufacturing footprints, and using flexible contract manufacturing relationships to maintain continuity in times of trade disruption. Third, proactive regulatory engagement can shorten time-to-field by clarifying data expectations and leveraging harmonized approval pathways where available. Fourth, companies should expand partnerships with veterinarians and farm service providers to embed vaccination into comprehensive herd health programs that include diagnostics, data analytics, and training. Finally, investing in digital tools for supply-chain visibility, cold-chain monitoring, and compliance tracking will improve operational reliability and provide actionable data to optimize immunization outcomes. These steps, taken together, form an actionable roadmap to enhance product relevance, commercial traction, and farm-level impact.

Transparent overview of the mixed-method research approach that integrated primary interviews, literature synthesis, segmentation mapping, and expert validation to derive actionable insights

The research underpinning this analysis combined qualitative and quantitative techniques to ensure robust, triangulated insights across the vaccine value chain. Primary research included structured interviews with veterinarians, farm managers, manufacturers, distributors, and regulatory specialists to capture frontline experience and strategic priorities. Secondary research involved systematic review of scientific literature, regulatory guidance, patent filings, and production system analyses to contextualize technological and policy trends. These inputs were synthesized using a triangulation approach that reconciled disparate perspectives and validated emerging themes.

Segmentation mapping was applied to align product attributes with end-user needs, administration realities, and distribution pathways. A cross-validation stage incorporated independent expert review panels to challenge assumptions and refine recommendations. Methodological limitations were addressed by documenting data gaps and uncertainty ranges, and by emphasizing qualitative implications where quantitative precision was constrained. Ethical considerations and confidentiality protocols guided interview conduct and the anonymization of proprietary information. Together, these methods produced a defensible and actionable evidence base designed to inform decision-making across R&D, manufacturing, regulatory, and commercial domains.

Concise synthesis highlighting the strategic priorities and coordinated actions necessary for translating vaccine innovation into sustained improvements in swine health and production resilience

Vaccination remains the most effective and scalable tool to protect swine health, preserve production continuity, and support public confidence in the pork supply chain. The industry stands at an inflection point where scientific progress, shifting trade dynamics, and changing farm practices demand coordinated responses from manufacturers, veterinarians, and policy makers. Success will depend on aligning innovation pipelines with practical delivery mechanisms, strengthening regional manufacturing and supply resilience, and deepening partnerships that translate scientific advances into routine herd-level practices.

In the short term, stakeholders should focus on operational measures that preserve continuity-diversifying suppliers, optimizing inventory strategies, and improving cold-chain oversight. In the medium term, investments in adaptable vaccine platforms, streamlined regulatory strategies, and expanded field support capabilities will determine which organizations lead in both developed and emerging markets. Ultimately, the capacity to convert technical superiority into accessible, implementable solutions for diverse end users will define market leadership and, more importantly, drive measurable improvements in animal health and farm sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Swine Vaccines Market, by Vaccine Type

  • 8.1. Dna Vaccine
  • 8.2. Inactivated Vaccine
  • 8.3. Live Attenuated Vaccine
  • 8.4. Recombinant Vaccine
  • 8.5. Subunit Vaccine
  • 8.6. Toxoid Vaccine

9. Swine Vaccines Market, by Animal Age

  • 9.1. Breeders
    • 9.1.1. Boars
    • 9.1.2. Sows
  • 9.2. Finishers
  • 9.3. Growers
  • 9.4. Piglets
  • 9.5. Weaners

10. Swine Vaccines Market, by Route Of Administration

  • 10.1. Injection
  • 10.2. Nasal
  • 10.3. Oral

11. Swine Vaccines Market, by Packaging Type

  • 11.1. Multi Dose Bottle
  • 11.2. Pre Filled Syringe
  • 11.3. Vial

12. Swine Vaccines Market, by End User

  • 12.1. Commercial Farms
  • 12.2. Research Institutes
  • 12.3. Veterinary Clinics
  • 12.4. Veterinary Hospitals

13. Swine Vaccines Market, by Disease Type

  • 13.1. Classical Swine Fever
  • 13.2. Erysipelas
  • 13.3. Mycoplasma Pneumonia
  • 13.4. Porcine Circovirus
  • 13.5. Porcine Reproductive And Respiratory Syndrome
  • 13.6. Swine Influenza

14. Swine Vaccines Market, by Distribution Channel

  • 14.1. Online Pharmacies
    • 14.1.1. Company Websites
    • 14.1.2. E Commerce Platforms
  • 14.2. Veterinary Clinics
  • 14.3. Veterinary Hospitals

15. Swine Vaccines Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Swine Vaccines Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Swine Vaccines Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Swine Vaccines Market

19. China Swine Vaccines Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Bimeda Holdings plc
  • 20.6. Biogenesis Bago S.A.
  • 20.7. Biovac Ltd.
  • 20.8. Bioveta, a.s.
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Ceva Sante Animale SA
  • 20.11. China Animal Husbandry Industry Co., Ltd.
  • 20.12. Elanco Animal Health Incorporated
  • 20.13. Hester Biosciences Limited
  • 20.14. HIPRA Laboratories, S.A.
  • 20.15. Hygieia Biological Laboratories (private company)
  • 20.16. IDT Biologika GmbH
  • 20.17. Indian Immunologicals Limited
  • 20.18. Intervet Inc.
  • 20.19. Jinyu Bio-Technology Co., Ltd.
  • 20.20. KM Biologics Co., Ltd.
  • 20.21. Komipharm International Co., Ltd.
  • 20.22. Kyoritsu Seiyaku Corporation
  • 20.23. Lohmann Animal Health International GmbH & Co. KG
  • 20.24. Merck & Co., Inc.
  • 20.25. Phibro Animal Health Corporation
  • 20.26. Vetoquinol S.A.
  • 20.27. Virbac S.A.
  • 20.28. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SWINE VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SWINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SWINE VACCINES MARKET SIZE, BY DNA VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SWINE VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SWINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SWINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SWINE VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SWINE VACCINES MARKET SIZE, BY TOXOID VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SWINE VACCINES MARKET SIZE, BY BOARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SWINE VACCINES MARKET SIZE, BY SOWS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SWINE VACCINES MARKET SIZE, BY FINISHERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SWINE VACCINES MARKET SIZE, BY GROWERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SWINE VACCINES MARKET SIZE, BY PIGLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SWINE VACCINES MARKET SIZE, BY WEANERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SWINE VACCINES MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SWINE VACCINES MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SWINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SWINE VACCINES MARKET SIZE, BY MULTI DOSE BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SWINE VACCINES MARKET SIZE, BY PRE FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SWINE VACCINES MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SWINE VACCINES MARKET SIZE, BY COMMERCIAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SWINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SWINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SWINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SWINE VACCINES MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SWINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SWINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SWINE VACCINES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SWINE VACCINES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SWINE VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SWINE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS SWINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SWINE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. GCC SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. GCC SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. G7 SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. G7 SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. NATO SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. NATO SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL SWINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA SWINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA SWINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA SWINE VACCINES MARKET SIZE, BY ANIMAL AGE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA SWINE VACCINES MARKET SIZE, BY BREEDERS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA SWINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA SWINE VACCINES MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA SWINE VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA SWINE VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA SWINE VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA SWINE VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)